Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in Japanese Adult Lower-risk MDS Patients With Platelet Transfusion Dependence
NCT04797000Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2021
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eltrombopag in myelodysplastic syndrome (MDS), sponsored by Novartis. Started May 2021; status: active, not recruiting.
02
Drugs
eltrombopag
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04797000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04797000.